-
公开(公告)号：WO2021207599A1
公开(公告)日：2021-10-14
申请号：PCT/US2021/026577
申请日：2021-04-09
Applicant: AKSTON BIOSCIENCES CORPORATION
Inventor： ZION, Todd C. , LANCASTER, Thomas M. , SATHIYASEELAN, Thillainayagam , HUANG, Kexin
IPC: C07K14/005 , A61K39/12 , A61P31/14 , A61K38/00 , A61K2039/54 , A61K2039/55566 , A61K2039/55588 , A61K2039/6031 , A61K2039/6056 , A61K2039/6075 , A61K2039/62 , A61K39/215 , C07K14/165 , C07K2319/30 , C12N2770/20022 , C12N2770/20034 , C12N7/00
Abstract: The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (CQVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naive patients to produce antibodies to the S ARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.
-
公开(公告)号：WO2018107117A1
公开(公告)日：2018-06-14
申请号：PCT/US2017/065456
申请日：2017-12-08
Applicant: AKSTON BIOSCIENCES CORPORATION
IPC: A61K38/00 , A61K38/28 , C07K14/435 , C07K14/62 , C07K19/00
Abstract: The present disclosure relates generally to compositions of insulin-Fc ( e.g. , proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g. , autoimmune diabetes, e.g. , Type 1 diabetes.
-
公开(公告)号：WO2023064711A2
公开(公告)日：2023-04-20
申请号：PCT/US2022/077752
申请日：2022-10-07
Applicant: AKSTON BIOSCIENCES CORPORATION
Inventor： LANCASTER, Thomas M. , ZION, Todd C.
Abstract: The present disclosure provides ultra-long acting insulin-Fc fusion proteins manufactured in a fungal strain for high yields and for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Production of the insulin-Fc fusion protein in a fungal strain provides unexpectedly high yields enabling a significant reduction in manufacturing costs. Fungal strain manufactured exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.
-
公开(公告)号：WO2023004406A2
公开(公告)日：2023-01-26
申请号：PCT/US2022/074036
申请日：2022-07-22
Applicant: AKSTON BIOSCIENCES CORPORATION
Inventor： ZION, Todd C. , LANCASTER, Thomas M.
Abstract: The present disclosure relates to compositions of fusion proteins, e.g. insulin-Fe fusion proteins, and their use to treat cancer cells and cancer tumors. The technology comprises a pharmaceutical composition for inhibiting cancer cell metabolism, growth, and/or proliferation, wherein the pharmaceutical composition comprises a fusion protein dispersed in a pharmaceutically acceptable carrier, the fusion protein comprising an insulin polypeptide and an Fe fragment, wherein the insulin polypeptide and the Fe fragment are connected by a linker
-
-
-
Search Results
4
records
(took 0.012 seconds)
